Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAROLYN trial of lisocabtagene maraleucel as first-line therapy for transplant-ineligible primary central nervous system lymphoma
2025-521144-38-00Phase 2Authorised
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2025
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of lisocabtagene maraleucel in primary central nervous system lymphoma (PCNSL), sponsored by Bristol Myers Squibb. Primary endpoint: Progression or death within 12 months after liso-cel. Planned start Dec 2025; status: authorised.
02
Drugs
lisocabtagene maraleucel
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on 2025-521144-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521144-38-00.